可瑞松联合重组人干扰素a-1b治疗毛细支气管炎疗效分析

Efficacy of combination of betamethasone sodium phosphate and recombinant human α-1b for bronchiolitis

目的:探讨可瑞松联合重组人干扰素a-1b(运德素)治疗毛细支气管炎的效果。方法:126例毛细支气管炎患儿随机分为观察组(64例)和对照组(62例),在常规处理的基础上,观察组应用可瑞松联合重组人干扰素a-1b(运德素)治疗,对照组应用甲基强的松龙和利巴韦林进行治疗,对两组的治疗效果、症状消失时间及住院时间进行比较分析。结果:观察组总有效率为93.75%;对照组总有效率为72.58%,两组总有效率比较差异有统计学意义(P<0.05);两组的症状消失时间及住院时间的差异也均有统计学意义(P均<0.05)。结论:与甲基强的松龙和利巴韦林比较,可瑞松联合重组人干扰素a-1b(运德素)治疗毛细支气管炎的临床有效率高,可以更快的缓解症状体征和缩短疗程。

Objective; To observe therapeutic effects of combination of betamethasone sodium phosphate and recombinant Human ^-lb on bronchiolitis. Methods： A total of 126 pediatric pat bronchioritis were randomly divided into observation group （n=64） and control group （n=62）. conventional therapy, the observation group was treated with combination of betamethasone sod ents with Based on um phos- phate and recombinant human a-1b, while the control group was given prednisolone and ribavirin. Thera- peutic effects, time course for symptoms disappearance, length of hospital stay were observed and compared between the two groups. Results： The total effective rate of the treatment group was 93.75%, significant higher than 72.58% of the control group. Significant difference in time course for symptoms disappearance, length of hospital stay was also observed between the two groups （P both 〈0.05）. Conclusions： Combination of betamethasone sodium phosphate and recombinant human a-1b can relieve symptoms and signs, shorten treatment course for patients with bronchioritis.